PHARMACOLOGICAL TREATMENT OF PTSD WITH PSYCHEDELICS: A FUTURE OUTLOOK

About 3.9% of people worldwide experience Post Traumatic Stress Disorder (PTSD) in their lifetime, a condition marked by intrusive thoughts, hyperarousal, and avoidance after trauma. Standard treatments like psychotherapy and medication help only modestly for many, leaving chronic symptoms and related health problems. This narrative review synthesizes current knowledge on novel treatments, focusing on psychedelic drugs. It examines research on psychedelic therapy for PTSD, weighing benefits and drawbacks of different interventions, and asks what psychedelic-based pharmacological treatments exist or are emerging for PTSD patients and how they might be integrated into future clinical care. The review aims to offer practitioners and patients insights into the potential role of psychedelic compounds in PTSD treatment.

Study at a glance

Abstract

Globally, approximately 3.9% of the population is estimated to experience Post Traumatic Stress Disorder during their lifetime. PTSD is characterized as a complex mental health condition that develops following exposure to traumatic events, manifesting through intrusive thoughts, hyperarousal, and avoidance behaviors. Despite psychotherapy and conventional pharmacotherapy being the standard primary treatments, a significant number of individuals with PTSD continue to suffer from chronic symptoms and substantial psychiatric and medical comorbidities, underscoring a critical need for innovative therapeutic interventions. A broad consensus in the literature indicates that existing PTSD treatments offer only marginal effectiveness for a considerable proportion of affected individuals. To address this, the present narrative review endeavors to synthesize the available knowledge regarding novel treatments for PTSD, specifically focusing on psychedelic drugs, acknowledging the current limitations in high-quality empirical literature on the subject. The primary objective of this study is to conduct a narrative review on the efficacy of psychedelic therapy in managing PTSD. This involves examining current research and evaluating the benefits and drawbacks associated with various psychedelic interventions. The central clinical question explored is: For patients diagnosed with PTSD, what are the current and emerging psychedelic-based pharmacological treatments, and what is their prospective role in future clinical integration? It is anticipated that this study will provide valuable insights to both practitioners and patients regarding the potential utility of psychedelic compounds within the therapeutic landscape of PTSD.